Related Experiment Videos
In vivo antiviral activity of recombinant murine gamma interferon
Abstract:
Recombinant murine gamma interferon (gamma-IFN) was tested for its antiviral activity in vivo. IFN preparations purified to greater than 95% purity were administered to CD-1 mice infected with lethal doses of encephalomyocarditis (EMC) virus. An initial treatment with rMuIFN-gamma administered 4 h prior to infection with virus, followed by daily treatment for 3 consecutive days significantly protected mice against EMC virus as evidenced by animal survival after 3-4 weeks post-viral infection. Variations in the antiviral effect relative to dose levels and routes of administration were also studied.
Insights
Recombinant murine gamma interferon (gamma-IFN) demonstrated significant antiviral protection against encephalomyocarditis (EMC) virus in mice. This study highlights gamma-IFN
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Recombinant murine gamma interferon (rMuIFN-gamma) is a cytokine with known immunomodulatory functions.
- Encephalomyocarditis virus (EMC) is a potent pathogen causing significant mortality in murine models.
- Understanding in vivo antiviral efficacy of interferons is crucial for developing therapeutic strategies.
Purpose of the Study:
- To evaluate the in vivo antiviral activity of recombinant murine gamma interferon (rMuIFN-gamma) against encephalomyocarditis virus (EMC) infection.
- To determine the protective effects of rMuIFN-gamma in a lethal EMC virus mouse model.
- To investigate dose-dependency and route variations in the antiviral response.
Main Methods:
- Purified rMuIFN-gamma preparations (>95% purity) were administered to CD-1 mice.
- Mice were infected with lethal doses of EMC virus.
- Treatment regimens included pre-infection administration and daily follow-up treatments over 3 days; dose and route variations were explored.
Main Results:
- A significant protective effect against EMC virus was observed in mice treated with rMuIFN-gamma.
- Survival rates were notably improved in treated animals compared to controls after 3-4 weeks post-infection.
- Antiviral efficacy varied based on the administered dose and route of rMuIFN-gamma.
Conclusions:
- Recombinant murine gamma interferon exhibits significant in vivo antiviral activity against EMC virus.
- Early and sustained administration of rMuIFN-gamma can protect against lethal viral challenge.
- Dose and route of administration are critical factors influencing the therapeutic outcome.